Literature DB >> 26431580

Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human T(H)2 cell subpopulation with enhanced function.

Alyssa Mitson-Salazar1, Yuzhi Yin1, Daniel L Wansley1, Michael Young2, Hyejeong Bolan1, Sarah Arceo1, Nancy Ho3, Christopher Koh3, Joshua D Milner1, Kelly D Stone1, Stephen A Wank3, Calman Prussin4.   

Abstract

BACKGROUND: IL-5(+) pathogenic effector T(H)2 (peT(H)2) cells are a T(H)2 cell subpopulation with enhanced proinflammatory function that has largely been characterized in murine models of allergic inflammation.
OBJECTIVE: We sought to identify phenotype markers for human peT(H)2 cells and characterize their function in patients with allergic eosinophilic inflammatory diseases.
METHODS: Patients with eosinophilic gastrointestinal disease (EGID), patients with atopic dermatitis (AD), and nonatopic healthy control (NA) subjects were enrolled. peT(H)2 and conventional T(H)2 (cT(H)2) cell phenotype, function, and cytokine production were analyzed by using flow cytometry. Confirmatory gene expression was measured by using quantitative RT-PCR. Prostaglandin D2 levels were measured with ELISA. Gut T(H)2 cells were obtained by means of esophagogastroduodenoscopy.
RESULTS: peT(H)2 cells were identified as chemoattractant receptor-homologous molecule expressed on T(H)2 cells-positive (CRTH2(+)), hematopoietic prostaglandin D synthase-positive CD161(hi) CD4 T cells. peT(H)2 cells expressed significantly greater IL-5 and IL-13 than did hematopoietic prostaglandin D synthase-negative and CD161(-) cT(H)2 cells. peT(H)2 cells were highly correlated with blood eosinophilia (r = 0.78-0.98) and were present in 30- to 40-fold greater numbers in subjects with EGID and those with AD versus NA subjects. Relative to cT(H)2 cells, peT(H)2 cells preferentially expressed receptors for thymic stromal lymphopoietin, IL-25, and IL-33 and demonstrated greater responsiveness to these innate pro-TH2 cytokines. peT(H)2 but not cT(H)2 cells produced prostaglandin D2. In patients with EGID and those with AD, peT(H)2 cells expressed gut- and skin-homing receptors, respectively. There were significantly greater numbers of peT(H)2 cells in gut tissue from patients with EGID versus NA subjects.
CONCLUSION: peT(H)2 cells are the primary functional proinflammatory human T(H)2 cell subpopulation underlying allergic eosinophilic inflammation. The unambiguous phenotypic identification of human peT(H)2 cells provides a powerful tool to track these cells in future pathogenesis studies and clinical trials. Published by Elsevier Inc.

Entities:  

Keywords:  Atopic dermatitis; CD161; CD294; CD4; IL-5; T(H)2; chemoattractant receptor–homologous molecule expressed on T(H)2 cells; eosinophilic gastrointestinal disease; eosinophilic inflammation; hematopoietic prostaglandin D synthase

Mesh:

Substances:

Year:  2015        PMID: 26431580     DOI: 10.1016/j.jaci.2015.08.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  49 in total

Review 1.  CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm.

Authors:  Kiyoshi Hirahara; Toshinori Nakayama
Journal:  Int Immunol       Date:  2016-02-12       Impact factor: 4.823

Review 2.  The immunopathology of lung fibrosis: amphiregulin-producing pathogenic memory T helper-2 cells control the airway fibrotic responses by inducing eosinophils to secrete osteopontin.

Authors:  Kiyoshi Hirahara; Ami Aoki; Yuki Morimoto; Masahiro Kiuchi; Mikiko Okano; Toshinori Nakayama
Journal:  Semin Immunopathol       Date:  2019-04-09       Impact factor: 9.623

Review 3.  Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Mei Lan Chen; Mark S Sundrud
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

4.  Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector TH2 subsets.

Authors:  David Chiang; Xintong Chen; Stacie M Jones; Robert A Wood; Scott H Sicherer; A Wesley Burks; Donald Y M Leung; Charuta Agashe; Alexander Grishin; Peter Dawson; Wendy F Davidson; Leah Newman; Robert Sebra; Miriam Merad; Hugh A Sampson; Bojan Losic; M Cecilia Berin
Journal:  J Allergy Clin Immunol       Date:  2018-01-31       Impact factor: 10.793

5.  Pathogenicity of acquired immunity in human diseases.

Authors:  Kiyoshi Hirahara
Journal:  Semin Immunopathol       Date:  2019-05-07       Impact factor: 9.623

Review 6.  Cell-by-cell deciphering of T cells in allergic inflammation.

Authors:  Ting Wen; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2019-11       Impact factor: 10.793

Review 7.  Pathogenic CD4+ T cells in patients with asthma.

Authors:  Lyndsey M Muehling; Monica G Lawrence; Judith A Woodfolk
Journal:  J Allergy Clin Immunol       Date:  2017-04-22       Impact factor: 10.793

Review 8.  Pathophysiology of Eosinophilic Esophagitis.

Authors:  Kelly M O'Shea; Seema S Aceves; Evan S Dellon; Sandeep K Gupta; Jonathan M Spergel; Glenn T Furuta; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2017-07-27       Impact factor: 22.682

Review 9.  Mechanisms that define transient versus persistent food allergy.

Authors:  M Cecilia Berin
Journal:  J Allergy Clin Immunol       Date:  2019-02       Impact factor: 10.793

10.  A cellular census of human lungs identifies novel cell states in health and in asthma.

Authors:  Felipe A Vieira Braga; Gozde Kar; Marijn Berg; Orestes A Carpaij; Krzysztof Polanski; Lukas M Simon; Sharon Brouwer; Tomás Gomes; Laura Hesse; Jian Jiang; Eirini S Fasouli; Mirjana Efremova; Roser Vento-Tormo; Carlos Talavera-López; Marnix R Jonker; Karen Affleck; Subarna Palit; Paulina M Strzelecka; Helen V Firth; Krishnaa T Mahbubani; Ana Cvejic; Kerstin B Meyer; Kourosh Saeb-Parsy; Marjan Luinge; Corry-Anke Brandsma; Wim Timens; Ilias Angelidis; Maximilian Strunz; Gerard H Koppelman; Antoon J van Oosterhout; Herbert B Schiller; Fabian J Theis; Maarten van den Berge; Martijn C Nawijn; Sarah A Teichmann
Journal:  Nat Med       Date:  2019-06-17       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.